Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04476420
Other study ID # 2130520HBOM
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date February 11, 2021
Est. completion date September 30, 2021

Study information

Verified date March 2022
Source Ziauddin University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oral submucous fibrosis (OSMF) is a potentially malignant condition mainly characterized by inflammation and fibrosis of the submucosal tissues leading to marked rigidity and reduced opening of the jaws. OSMF has a multifactorial etiology but areca nut consumption is considered to be the most consistent factor in its pathogenesis. There is no definitive treatment available for treating OSMF. Conventional management involves physiotherapy exercises and treating the disease with certain medications such as steroids and homeopathic medications.


Description:

OSMF is a chronic insidious disorder of the oral cavity which has a great potential to turn malignant. The clinical manifestations of OSMF comprise of white, marble-like appearance of the oral mucosa with loss of flexibility and formation of palpable fibrous bands extending from the anterior to the posterior region of the oral cavity.Other features include burning sensation on taking spicy food, loss of papillae of the tongue, loss of natural pigmentation of the lips and restricted mouth opening. There is no definitive treatment available for OSMF due to its complex etiology. The most essential component in the management of OSMF is the discontinuation of the habit of areca nut chewing by the patient followed by conservative or surgical treatment. Currently, steroids are the most commonly used drug group in managing OSMF because of their ability to reduce the inflammatory process and increasing the apoptosis of inflammatory cells thereby decreasing fibrosis. However, they are not very useful in reversing the pathology and restoring mucosal elasticity and can cause mucosal thinning with long term use ultimately resulting in worsening of the symptoms of the disease. Many in- vitro and in- vivo studies have been conducted to establish the anti neoplastic, anti inflammatory, immunomodulatory, antihypertensive, antimicrobial, anti-parasitic, antioxidant and hypoglycemic properties of N.sativa oil. Among all the constituents of Nigella sativa, Thymoquinone (Tq) is the most pharmacologically active constituent responsible for most of its properties. Nigella sativa has been used widely in different food preparations in the form of a flavoring agent or a spice. It is also recognized as 'safe' in the inventory of United States Food and Drug administration.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date September 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with the age of 18 years and above - Patients clinically diagnosed with Oral submucous fibrosis - Patients who have not received any treatment for Oral submucous fibrosis in the last three months. - Patients who are willing to quit the habit of eating pan, gutka and areca nut - Patients who are willing to attend the follow up visits Exclusion Criteria: - Patients who are less than 18 years of age - Patients who are already using pain medications, corticosteroids or immunosuppressive drugs in any other form - Patients with a history of malignancy - Patients presenting with oral lesions other than Oral submucous fibrosis (OSMF) - Patients who are allergic to the drug material used in the clinical trial - Patients who will not give consent

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Nigella sativa oil
Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.
Drug:
Betamethasone Valerate
it is a conventionally used drug for treating OSMF

Locations

Country Name City State
Pakistan Ziauddin University, Clifton Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Ziauddin University

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain assessed using visual analogue scale (VAS) Pain will be measured using VAS. This scale usually present as a 100-mm horizontal line on which the pain intensity experienced by the patient will be represented by a point between the extremes of "no pain at all" and "worst pain imaginable. 6 months
Primary Inter-incisal mouth opening (IMO) assessed using vernier caliper Interincisal mouth opening will be calculated by measuring the distance between the mesioincisal angles of the maxillary central incisor and the mandibular central incisor with the help of a vernier calliper. 6 months
Secondary Cheek Flexibility assessed following the method of Mathur and Jha (1993) A line will be drawn from the tragus of the ear to the angle of the mouth and then two reference points will be marked on both the cheeks at 1/3rd the distance from the angle of the mouth on the line drawn previously. After marking these reference points, the patient will be asked to blow his cheek and the distance will be measured between the two points. Then the patient will be instructed to relax his cheeks and the distance will be measured again. The difference between the two values will give the value for cheek flexibility. 6 months
Secondary Tongue protrusion Tongue protrusion will be recorded by measuring the distance between the tip of the tongue and the mesioincisal angle of the upper central incisor using steel ruler. 6 months
See also
  Status Clinical Trial Phase
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Not yet recruiting NCT06332612 - Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial Phase 1/Phase 2
Completed NCT02711046 - Use of Single Staged Nasolabial Flap in Oral Submucous Fibrosis N/A
Completed NCT03011086 - Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis N/A
Recruiting NCT03511261 - Efficacy of Curcumin in Oral Submucous Fibrosis Phase 2
Completed NCT03732872 - Epithelial Mesenchymal Transition Markers in OSMF
Active, not recruiting NCT02645656 - Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF) Phase 2
Not yet recruiting NCT04487938 - Oral Cancer Screening and Education in Hong Kong